Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Go back to Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)| (NASDAQ: SVRA) | Delayed: 5.69 +0.19 (3.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.50 | 52 Week High | $ | |||
| Open | $5.59 | 52 Week Low | $ | |||
| Day High | $5.79 | P/E | N/A | |||
| Day Low | $5.50 | EPS | $ | |||
| Volume | 2,290,385 | |||||
